Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
-NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Campaign Update
 

NHF is pleased to announce that Novo Nordisk, Visionary Corporate Partner and Lead Benefactor of Campaign for Our Future, has renewed its commitment to the Campaign with an additional $600,000 to kick-start Phase II of the Campaign.  Joining Novo Nordisk in support of the Campaign is an anonymous NHF chapter supporter of research, who has committed $150,000 over the next three years, designated to expanding the Judith Graham Pool Postdoctoral Research Fellowship program.

 

With more than 90% of the goal already reached for Campaign for Our Future, NHF recently launched the public phase of its fundraising campaign. Phase II--Campaign for Our Future, Research is Our Future--has a specific focus on cutting-edge research.  “NHF will be engaging in a more aggressive research agenda that will expand our current research portfolio while leveraging all of the necessary resources needed to significantly advance our cause,” said Val Bias, NHF CEO. Novo Nordisk has recognized this and has generously provided seed money to support a series of interventions, part of a Research Catalyst Fund. “Our support of NHF is part of our overall commitment to ‘changing possibilities in hemophilia’ and is completely consistent with our values as a corporation,” said Eddie Williams, Vice President, Biopharmaceuticals, Novo Nordisk.

 

Cultivating the interest of professionals to join and stay in the field of hemophilia; building coalitions with other chronic disease groups, government agencies, and biotech companies; and convening clinical experts are all part of a long-term vision that that will move us toward better treatments, and ultimately, a cure.  This major commitment from Novo Nordisk also enables NHF to expand its base of support, by acting as the catalyst for the public phase of the Campaign, through which we will engage all stakeholders, particularly individuals and families. “Novo Nordisk's support has brought us halfway to our Phase II fundraising goal of $1.2 million, and along with chapter support, we are close to the finish line.  However, we need the support of the entire community to fully reach our goals,” said Bias.

 

Almost every major medical advancement in the treatment and care of people with bleeding disorders has been made possible through funding from caring individuals who understand firsthand the importance of scientific discovery.  Individuals and families will play a vital role in helping raise the final $450,000 that will bring the Campaign to a close.  “We have done it before, and with your support, we can do it again,” adds Bias.

 

NHF thanks our 2010 Corporate Partners of the Campaign for our Future: Visionary Corporate Partner and Lead Benefactor Novo Nordisk; Principal Corporate Partner Baxter; Major Corporate Partners Bayer HealthCare and CSL Behring; and Corporate Partner Grifols.

 

Learn more about Campaign for Our Future, Research is Our Future.

 

 

This section of our Web site is sponsored by: